# US 2014/0273006 A1 · Method of therapy selection for patients with cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0273006 A1
- Document ID: US20140273006A1
- Status: Published application
- Kind: A1
- Application number: 14/294,449
- Filed: 2014-06-03
- Published: 2014-09-18
- Earliest claimed: 2011-12-05
- Applicants: Nestec S.A.
- Inventors: Sharat Singh; Anne Kuller; Tani Ann T. Lee; Saswati Hazrar; Richard Kirkland; Xinjun Liu; Phillip Kim
- Web page: https://patentgrep.com/patent/US20140273006A1

## CPC

- G01N 33/5758: {involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites}
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- G01N 33/542: with steric inhibition or signal modification, e.g. fluorescent quenching
- G01N 33/57585: {involving compounds identifiable in body fluids}
- G01N 33/5759: {involving compounds localised on the membrane of tumour or cancer cells}
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides methods for detecting, measuring and quantitating the expression and activation states of signal transduction analytes in cells such as tumor cells. The invention also provides methods for selecting therapy, optimizing therapy, monitoring therapeutic efficacy, and/or detecting therapeutic resistance. Accordingly, the methods are useful for improving cancer therapy selection and disease monitoring.

## Claims

### Claim 1

A method for selecting treatment for a subject diagnosed with cancer, the method comprising:
(a) measuring the expression and/or activation level of one or more signal transduction analytes selected from a group consisting of HER1, HER2, HER3, cMET, IGF-1R, PI3K, AKT, ERK, MEK, p70S6K, PDK1, PRAS40, PTEN, RPS6, SHC, and combinations thereof in a sample taken from the subject using a proximity assay to determine a pathway profile; and
(b) recommending a targeted inhibitor therapy by determining whether the subject is likely to respond to the targeted inhibitor therapy based on the subject's pathway profile.

### Claim 2 (depends on 1)

The method of claim 1, wherein the cancer is selected from the group consisting of breast, colorectal, gastric, lung, pancreatic, and prostate cancer.

### Claim 3 (depends on 1)

The method of claim 1, wherein step (a) further comprising comparing the subject's pathway profile to a reference pathway profile.

### Claim 4 (depends on 3)

The method of claim 3, wherein the reference pathway profile is determined using a sample from a cancer cell line.

### Claim 5 (depends on 3)

The method of claim 3, wherein the reference pathway profile is determined using a sample from a subject having a specific type of cancer.

### Claim 6 (depends on 1)

The method of claim 1, wherein the proximity assay is a Collaborative Enzyme Enhanced Reactive immunoassay (CEER).

### Claim 7 (depends on 1)

The method of claim 1, wherein the targeted inhibitor is selected from a group consisting of a tyrosine kinase inhibitor, a PI3K inhibitor, a MEK inhibitor, a HER2 inhibitor, a HER3 inhibitor or combinations thereof.

### Claim 8 (depends on 7)

The method of claim 7, wherein the PI3K inhibitor is selected form the group consisting of BYL719, BAY841236, BAY806946, SF1126, XL147, XL765, NVP-BEZ235, NVP-BGT226, NVP-BKM120, GDC-0941, PX-866, GSK1059615, CAL-101, and combinations thereof.

### Claim 9 (depends on 7)

The method of claim 7, wherein the MEK inhibitor is selected form the group consisting of BAY869766, MEK162, GDC-0973/RG7420, GDC-0623/RG7421, RG7167, RG7304, XL518, PD-325901, and combinations thereof.

### Claim 10 (depends on 7)

The method of claim 7, wherein the HER2 inhibitor is selected from the group consisting of trastuzumab, trastuzumab-DM1 ertumaxomab, gefitinib, erlotinib, pelitinib, CP-654577, CP-724714, canertinib/CI-1033/PD183805, HKI-272, lapatinib, neratinib, PKI-166/CGP-75166, AEE788, BMS-599626, HKI-727, HKI-357, BIBW 2992, AG1478, Arry-380, ARRY-334543, Bay846, D69491, DXL-702, JNJ-26483327, and combinations thereof.

### Claim 11 (depends on 7)

The method of claim 7, wherein the HER3 inhibitor is selected from the group consisting of MM-121, AMG-888, trastuzumab, pertuzumab, cetuximab, MEHD7945A/RG7597, RG7116, gefitinib, erlotinib, canertinib, lapatinib, MP-470, AZD8931, PF00299804; and combinations thereof.

### Claim 12 (depends on 1)

The method of claim 1, wherein the sample is a fine needle aspirate, a tumor tissue biopsy, a tumor cell, or a circulating tumor cell.

### Claim 13

A method for optimizing therapy or monitoring therapeutic efficacy of a targeted inhibitor for a subject with cancer, the method comprising:
(a) measuring the expression and/or activation level of one or more signal transduction analytes selected from a group consisting of HER1, HER2, HER3, cMET, IGF-1R, PI3K, AKT, ERK, MEK, p70S6K, PDK1, PRAS40, PTEN, RPS6, SHC, and combinations thereof in a sample taken from the subject at a plurality of time point over the course of therapy with the targeted inhibitor to determine a pathway profile;
(b) determining whether the subject is responsive to the targeted inhibitor based on the subject's pathway profile; and
(c) recommending the administration of the targeted inhibitor be continued if the subject is responsive.

### Claim 14 (depends on 13)

The method of claim 13, further comprising recommending the administration of the targeted inhibitor be modified if the subject is non-responsive.

### Claim 15 (depends on 14)

The method of claim 14, further comprising recommending the administration of at least two targeted inhibitors if the subject is non-responsive.

### Claim 16 (depends on 13)

The method of claim 13, wherein the first time point in the plurality of time points is prior to the course of therapy with the targeted inhibitor.

### Claim 17 (depends on 13)

The method of claim 13, wherein the subsequent time point or points in the plurality of time points is during the course of therapy with the targeted inhibitor.

### Claim 18 (depends on 13)

The method of claim 13, wherein the cancer is selected from the group consisting of breast, colorectal, gastric, lung, pancreatic, and prostate cancer.

### Claim 19 (depends on 13)

The method of claim 13, wherein the sample is a fine needle aspirate, a tumor tissue biopsy, a tumor cell, or a circulating tumor cell.

### Claim 20 (depends on 13)

The method of claim 13, wherein the targeted inhibitor is selected from a group consisting of a tyrosine kinase inhibitor, a PI3K inhibitor, a MEK inhibitor, a HER2 inhibitor, a HER3 inhibitor, or combinations thereof.

### Claim 21 (depends on 20)

The method of claim 20, wherein the PI3K inhibitor is selected from the group consisting of BYL719, BAY841236, BAY806946, SF1126, XL147, XL765, NVP-BEZ235, NVP-BGT226, NVP-BKM120, GDC-0941, PX-866, GSK1059615, CAL-101, and combinations thereof.

### Claim 22 (depends on 20)

The method of claim 20, wherein the MEK inhibitor is selected from the group consisting of BAY869766, MEK162, GDC-0973/RG7420, GDC-0623/RG7421, RG7167, RG7304, XL518, PD-325901, and combinations thereof.

### Claim 23 (depends on 20)

The method of claim 20, wherein the HER2 inhibitor is selected from the group consisting of trastuzumab, trastuzumab-DM1 ertumaxomab, gefitinib, erlotinib, pelitinib, CP-654577, CP-724714, canertinib/CI 1033/PD183805, HKI-272, lapatinib, neratinib, PKI-166/CGP-75166, AEE788, BMS-599626, HKI-727, HKI-357, BIBW 2992, AG1478, Arry-380, ARRY-334543, Bay846, D69491, DXL-702, JNJ-26483327, and combinations thereof.

### Claim 24 (depends on 20)

The method of claim 20, wherein the HER3 inhibitor is selected from the group consisting of MM-121, AMG-888, trastuzumab, pertuzumab, cetuximab, MEHD7945A/RG7597, RG7116, gefitinib, erlotinib, canertinib, lapatinib, MP-470, AZD8931, PF00299804; and combinations thereof.
